HIGHLIGHTS
- who: Jingyi Liu from the University of of Medicine, Lexington, KY, USA have published the research: Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: The study provides several potential therapeutic strategies for overcoming drug resistance in luminal breast cancer. Lastly, the study provides a new mechanistic insight regarding FOXO3a-mediated gene transcription. The study demonstrated that FOXO3a uses its di-acetylation motif to recruit BRD4 and RNA Polymerase II for activating gene transcription.
SUMMARY
From several studies indicate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.